Die German Breast Group sowie andere nationale und internationale Studiengruppen empfehlen die Teilnahme an Therapiestudien. Derzeit bieten unterschiedliche Organisationen hochwertige Studien zur Behandlung von Frauen mit bösartigen Erkrankungen an. Über die folgenden Links erreichen Sie die Webseiten deutscher Studiengruppen und finden die jeweils aktuellen Therapiestudien.
German Breast Group
aktive Studien
Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO)
www.ago-online.de
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Studiengruppe
www.ago-ovar.de
Brustkrebs-Studien
www.brustkrebs-studien.de
Overview of our currently recruiting trials. Further studies are in planning.
Operable node-positive breast cancer:
TAXIS**
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy. All patients will receive breast/chest wall and regional nodal irradiation. Patients without axillary lymph node dissection will receive additional irradiation of the axilla.
Operable HER2-positive or triple-negative breast cancer:
EUBREAST-01
Omission of sentinel lymph node biopsy in patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy. All patients with confirmed breast pCR after lumpectomy will be selected for the single study arm leading to omission of any axillary treatment.
Operable triple-negative breast cancer:
ALEXANDRA
Arm A: Adjuvant chemotherapy with 12x paclitaxel weekly followed by EC/AC q2w + atezolizumab q2w followed by atezolizumab monotherapy q3w (total duration of atezolizumab will be one year)
Arm B: Chemotherapy alone
Operable HR-positive / HER2-negative breast cancer:
APPALACHES
Arm A: Palbociclib 2 years + standard adjuvant endocrine therapy ≥ 5 years
Arm B: Adjuvant chemotherapy followed by standard adjuvant endocrine therapy ≥ 5 years
HER2-negative breast cancer, non-pCR after NACT
or
SASCIA
Arm A: Sacituzumab govitecan 8 cycles d1,8 q3w
Arm B: Treatment of physician`s choice (8 cycles capecitabine or platinum-based chemotherapy or observation)
In patients with HR-positive breast cancer, endocrine therapy will be administered according to local guidelines.
HER2-positive breast cancer, non-pCR after NACT
or
TruDy/DESTINY-B05
Arm A: Trastuzumab deruxtecan 14 cycles d1 q3w
Arm B: Trastuzumab emtansine (T-DM1) 14 cycles d1 q3w
HER2-positive, HR-positive breast cancer
GeparPiPPa**
Arm A: Endocrine therapy in combination with ready-to-use fixed-dose combination of pertuzumab and trastuzumab s.c. (PH-FDC SC) q3w and inavolisib (6 cycles)
Arm B: Endocrine therapy and PH-FDC SC q3w (6 cycles)
Brain metastases of breast cancer
Brain Metastases in Breast Cancer (BMBC)
Retrospective and prospective registry designed to collect tumor characteristics of the primary and metastatic tumor as well as treatment data and biomaterial from patients diagnosed with brain metastases of breast cancer.
HER2-negative and HR-positive metastatic breast cancer :
PADMA
Endocrine therapy + palbociclib versus mono-chemotherapy +/- endocrine maintenance therapy
Possible mono-chemotherapies (Physician`s choice):
BRCA-P**
Study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation:
Denosumab 120mg s.c. every 6 months vs placebo s.c. every 6 months
Former GBG study participants in Germany
Patient self-reported outcome registry (PSRO)
Collection of long-term safety and efficacy parameters of former GBG study participants from prospective clinical trials. Data reporting by the patient via questionnaire.
Former GBG study participants other countries
ETERNITY-B
Registry for collection of long-term safety and efficacy parameters of former GBG study participants from prospective clinical trials. Data collection and documentation is performed study site.
** Planned start of recruitment QI-II/2022